Koffiekamer Terug naar discussie overzicht

Intellia Therapeutics 2024

1. Rick96 16 april 2024 15:48

   auteur info

   • Rick96

     Lid sinds: 24 apr 2020

     Laatste bezoek: 29 apr 2024

   • Aanbevelingen

     Ontvangen: 17

     Gegeven: 16

   •    Aantal posts: 59

   Nog geen beste keuze geweest..
2. Hoger Lager 17 april 2024 16:56

   auteur info

   • Hoger Lager

     Lid sinds: 04 okt 2023

     Laatste bezoek: 29 apr 2024

   • Aanbevelingen

     Ontvangen: 204

     Gegeven: 229

   •    Aantal posts: 277

   quote:

   Rick96 schreef op 16 april 2024 15:48:

   Nog geen beste keuze geweest..
   

   Door de oorlog zijn de meeste koersen gedaald. Ik zit LT
3. Hoger Lager 29 april 2024 17:08

   auteur info

   • Hoger Lager

     Lid sinds: 04 okt 2023

     Laatste bezoek: 29 apr 2024

   • Aanbevelingen

     Ontvangen: 204

     Gegeven: 229

   •    Aantal posts: 277

   Intellia Therapeutics, Inc.
   April 29, 2024 7:30 AM EDT
   Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
   Extended follow-up will include safety, kallikrein reduction and attack rate data, including number of patients who continue to be completely attack free through the latest follow-up
   Intellia to host investor webcast on Monday, June 3, at 8 a.m. ET
   CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the acceptance of an oral presentation from the Phase 1 portion of the ongoing NTLA-2002 Phase 1/2 study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, taking place May 31 – June 3 in Valencia, Spain. NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for hereditary angioedema (HAE), a rare genetic condition that leads to potentially life-threatening swelling attacks. The presentation will include updated safety and efficacy results from the Phase 1 study across all three dose cohorts (25 mg, 50 mg and 75 mg).
   
   Presentation Details
   
   Title: CRISPR-based gene editing of KLKB1 resulted in long-term plasma kallikrein protein reduction and decreased attack rate in patients with hereditary angioedema: Updated results from a phase 1 study
   
   Session: Breakthroughs in management of Hereditary Angioedema
   
   Date and Time: Sunday, June 2, 2024, from 8:30 – 10:00 a.m. CET
   
   Presenter: Hilary Longhurst, M.D., Ph.D., FRCP, FRCPath, Senior Medical Officer at Auckland District Health Board and Honorary Associate Professor at University of Auckland, New Zealand, the trial’s principal investigator in New Zealand